PROGRAMME DAY 3

Wednesday 28 September 2022

08:30 - 09:00

Plenary Session 3 | Main Auditorium
Novel Insights in the Antigenic Drift of Influenza Virus HA and NA
Ron Fouchier, Erasmus MC, Netherlands

Hideki Hasagawa, WHO Collaborating Centre for Reference and Research on Influenza, Japan

Looking Below the Surface - Influenza and COVID-19 in Africa
Cheryl Cohen, University of the Witwatersrand, South Africa

09:00 - 09:30

Virology & Pathogenesis
Clinical Sciences & Vaccinology
Public Health & Policy

Influenza: Transmission
COVID-19 Vaccine [focus: vaccines in use, late-stage development and pan-coronavirus vaccines]
Burden of Disease for Influenza and Dual Epidemics

Chair(s) TBC
Chair(s) TBC
Chair(s) TBC

10:00 - 10:30

Tea break | Hall 1

10:30 - 12:00

Influenza: Transmission
Chemical Sciences & Vaccinology
Public Health & Policy

Impact of acidic pH in respiratory aerosol on the inactivation times
The Mechanisms of Hemagglutinin and Neuraminidase Adaptation

Ali Zhang, McMaster University, Canada
Sho Miyamoto, National Institute of Infectious Diseases, Japan
Jordan Clark, The Ichan School of Medicine at Mount Sinai, USA

11:00 - 11:12

A naturally occurring NA stabilizing amino acid (HAI-Y17) in a low pathogenic influenza A (H1N1p0) virus contributes to virus airborne transmission [AOXI0006]
Xiangjie Sun, Centers for Disease Control and Prevention, USA

11:12 - 11:24

The Mechanisms of Hemagglutinin and Neuraminidase Adaptation in the Emergence of the 1968 H3N2 Pandemic Virus [AOXI0047]
Jie Zhou, Imperial College London, UK

11:24 - 11:36

Epidemiology and molecular analyses of Influenza B viruses in Senegal from 2010 to 2019 [AOXI0065]
Ndongo Dia, Institut Pasteur Dakar, Senegal

11:36 - 11:48

Impact of acidic pH in respiratory aerosol on the inactivation times of influenza and coronaviruses [AOXI0099]
Irina Glas, University of Zurich, Switzerland

11:48 - 12:00

Pathogenesis and infection dynamics of high pathogenicity avian influenza virus (HPAIV) H5N1 (Clade 2.3.4.4b) in pheasants and onward transmission to chickens [AOXI0058]
Yuan Liang, University of Copenhagen, Denmark

12:00 - 14:00

Lunch / sponsored symposium | Hall 1

14:00 - 14:30

Influenza - Innate Immune Response to Infection

Session Speaker: Seema Lakdawala
Emory University, USA

Sensing of self DNA amplifies innate immune responses to suppress influenza virus replication [AOXI0086]
Andrew Mehle, University of Wisconsin Madison, United States

14:30 - 14:42

Lung epithelial cell injury increases resistance to influenza virus infection in a type I interferon dependent manner [AOXI0102]
Sang Uk Seo, The Catholic University of Korea, Republic of Korea

14:42 - 15:05

Release of Influenza A virus vRNA-Ps by macrophages during abortive infection may shape innate responses [AOXI0037]
Sarah Lundrigan, University of Melbourne, Australia

14:54 - 15:05

Releasing Influenza A virus vRNA-Ps by macrophages during abortive infection may shape innate responses [AOXI0037]
Sarah Lundrigan, University of Melbourne, Australia

15:05 - 15:18

Integrated drivers of basal immunity and acute responses to influenza infection in diverse human populations [AOXI0045]
Aisha Saquette, St. Jude Children's Research Hospital, USA

15:06 - 15:18

Non-neutralizing antibodies provide protection against lethal challenge with SARS-CoV-2 in murine and hamster infection models [AOXI0016]
Jordan Clark, The Ichan School of Medicine at Mount Sinai, USA

15:18 - 15:30

Session Speaker: Kayvon Modjarrad
Walter Reed Army Institute of Research, USA

Development of a bivalent vaccine against SARS-CoV-2 and influenza using a live attenuated influenza vaccine platform [AOXI0023]
Irian isakova-Slivak, Institute of Experimental Medicine, Russian Federation

15:30 - 15:42

Non-neutralizing antibodies provide protection against lethal challenge with SARS-CoV-2 in murine and hamster infection models [AOXI0016]
Jordan Clark, The Ichan School of Medicine at Mount Sinai, USA

15:42 - 15:54

Development of a bivalent vaccine against SARS-CoV-2 and influenza using a live attenuated influenza vaccine platform [AOXI0023]
Irian Isakova-Slivak, Institute of Experimental Medicine, Russian Federation

15:54 - 16:06

Impact of heterotypic and heterosubtypic repeat influenza infection patterns in a pediatric cohort in Managua, Nicaragua [AOXI0013]
Eduardo Azziz-Baumgartner, Centers for Disease Control and Prevention, United States

16:06 - 16:18

Impact of heterotypic and heterosubtypic repeat influenza infection patterns in a pediatric cohort in Managua, Nicaragua [AOXI0013]
Eduardo Azziz-Baumgartner, Centers for Disease Control and Prevention, United States

16:18 - 16:30

The contribution of influenza to ischemic heart disease mortality worldwide [AOXI0026]
Sandra Chaves, Sanofi Vaccines, Belgium

16:30 - 17:00

Burden of Disease for Influenza and Dual Epidemics

Chair(s) TBC

17:00 - 17:30

Session Speaker: Jeremy Jones
St. Jude Children's Research Hospital, USA

Epidemiology and molecular analyses of Influenza B viruses in Senegal from 2010 to 2019 [AOXI0065]
Ndongo Dia, Institut Pasteur Dakar, Senegal

17:30 - 18:00

Session Speaker: Stacey Schultz-Cherry
Vir Biotechnology

Pathogenesis and infection dynamics of high pathogenicity avian influenza virus (HPAIV) H5N1 (Clade 2.3.4.4b) in pheasants and onward transmission to chickens [AOXI0058]
Yuan Liang, University of Copenhagen, Denmark

18:00 - 18:30

Session Speaker: David Muscatello
University of New South Wales, Australia

Development of a bivalent vaccine against SARS-CoV-2 and influenza using a live attenuated influenza vaccine platform [AOXI0023]
Irian Isakova-Slivak, Institute of Experimental Medicine, Russian Federation

18:30 - 19:00

Excess mortality from influenza and RSV during the COVID-19 pandemic in the US: a natural experiment to clarify the etiology of respiratory deaths [AOXI0027]
Chelsea Hansen, Fogarty International Center, United States

19:00 - 20:00

Session Speaker: TBC

The COVID-19 Scenario Modelling Hub: a multi-model effort to generate pandemic projections in the United States [AOXI0018]
Cecile Vibold, Fogarty International Center, United States

20:00 - 21:00

Session Speaker: Kayvon Modjarrad
Walter Reed Army Institute of Research, USA

Broadly-neutralizing antibodies that bind to the hemagglutinin stalk domain enhance the effectiveness of neuraminidase inhibitors via Fc-mediated effector functions [AOXI0056]
Ali Zhang, McMaster University, Canada

21:00 - 22:00

Session Speaker: TBC

Classification of different pandemic COVID-19-periods in Germany based on parameters from the Pandemic Influenza Severity Assessment Tool (PISA) [AOXI0021]
Kristin Tolksdorf, Robert Koch Institute, Germany

22:00 - 23:00

Session Speaker: TBC

Comparison Between Online and Face-to-face Health Education Approach for School Students of Hong Kong During the COVID-19 Pandemic Era [AOXI0055]
Jiajie Chen, University of Hong Kong, Hong Kong

23:00 - 00:00

Session Speaker: TBC

Using high-resolution social contact networks to evaluate SARS-CoV-2's transmission and control in large-scale multi-day events [AOXI0056]
Rachael Pung, London School of Hygiene and Tropical Medicine, UK.

00:00 - 01:00

Session Speaker: TBC

Combining forum discussions and surveys to evaluate influenza A (H1N1) pandemic E23X substitutions resistance in the USA [AOXI0017]
Jeremy Jones, St. Jude Children's Research Hospital, USA

01:00 - 02:00

Session Speaker: TBC

Pathogens and their interaction with the host in the Emergence of the 1968 H3N2 Pandemic Virus [AOXI0006]
Jie Zhou, Imperial College London, UK

02:00 - 03:00

Session Speaker: TBC

Novel Insights in the Antigenic Drift of Influenza Virus HA and NA
Ron Fouchier, Erasmus MC, Netherlands

03:00 - 04:00

Session Speaker: TBC

Non-neutralizing antibodies provide protection against lethal challenge with SARS-CoV-2 in murine and hamster infection models [AOXI0016]
Jordan Clark, The Ichan School of Medicine at Mount Sinai, USA

04:00 - 05:00

Session Speaker: TBC

Impact of heterotypic and heterosubtypic repeat influenza infection patterns in a pediatric cohort in Managua, Nicaragua [AOXI0013]
Eduardo Azziz-Baumgartner, Centers for Disease Control and Prevention, United States

05:00 - 06:00

Session Speaker: TBC

The contribution of influenza to ischemic heart disease mortality worldwide [AOXI0026]
Sandra Chaves, Sanofi Vaccines, Belgium

06:00 - 07:00

Session Speaker: TBC

Combining forum discussions and surveys to evaluate SARS-CoV-2's transmission and control in large-scale multi-day events [AOXI0056]
Rachael Pung, London School of Hygiene and Tropical Medicine, UK.
15:18 - 15:30
Analysis of mucosal innate immune responses to human and swine adapted influenza A viruses using swab samples [AOXI0173]
Helena Aagaard Glud, Technical University of Denmark, Denmark

Rapid Detection of Influenza Outbreaks in Long Term Care Facilities Reduces Emergency Room Visits and Hospitalization: Rapid Assessment of, and Prophylaxis for Influenza for Denizens of Long Term Care Facilities (RAPID-LTCF) [AOXI0165]
Jonathan Temza, University of Wisconsin School of Medicine and Public Health, USA

Daily Antigen Rapid Testing Surveillance (DARTS) System for COVID-19 - a large-scale ad-hoc participatory community surveillance initiative using self-performed lateral flow rapid antigen tests in Hong Kong [AOXI0350]
Dennis Ip, University of Hong Kong, Hong Kong

15:30 - 16:00

Tea break | Hall 1

16:00 - 16:05
Chair(s) tbc

16:06 - 16:18
Influenza - Adaptive Immune Response to Infection

Chair(s) tbc

16:18 - 16:30

COVID-19: Antivirals and Therapeutics

Chair: Dan Jernigan
U.S. Centers for Disease Control and Prevention

16:05 - 16:30

Pandemic Preparedness and Response II

16:06 - 16:18
Current efforts to prepare for the future respiratory pandemics: understanding public health and social measures [AOXI0007]
Ryoko Takahashi, World Health Organization, Switzerland

Enhancing Pandemic Preparedness - Understanding Global Population Needs for Pandemic Influenza Products [AOXI0011]
Ioana Ghiga, World Health Organization, Switzerland

16:05 - 16:30

Session Speaker: Carolien van de Sandt
University of Melbourne

Session Speaker: TBC

16:30 - 16:42
Increasing HbA1c levels reduces the CD8 T cell response to influenza virus in a TCR-dependent manner in individuals with diabetes mellitus [AOXI0277]
Katina Hulme, University of Queensland, Australia

Exploring determinants of response-ready influenza vaccination programs in five middle-income countries [AOXI0455]
Marissa Malchione, Sabin Vaccine Institute, United States

16:42 - 16:54
Revealing epitope hierarchies in human polyclonal antibody responses to antigenically drifting seasonal influenza A viruses [AOXI0435]
Juliana Han, Scripps Research Institute, United States

A framework for seroepidemiologic investigations in pandemics: insights from an evaluation of WHO's COVID-19 Unity Studies initiative [AOXI276]
Karen Hennessey, MM Global Health, Philippines

16:54 - 17:06
Low glycan occupancy of N-linked glycosylation sites on hemagglutinin is sufficient to divert adaptive immune responses to A(H3N2) influenza virus [AOXI0008]
Irina Alymova, Centers for Disease Control and Prevention, USA

Safety, pharmacokinetics and anti-drug antibodies following a second dose of AZD7442 (ticagrelor/clipagillin): open-label sub study of the PROVENT Phase 3 trial for symptomatic COVID 19 prevention [AOXI0394]
Andrew Ustianowski, North Manchester General Hospital, UK

Enhancing Influenza Surveillance through Cloud Computing Platforms [AOXI0084]
Peter Daly, Centers for Disease Control and Prevention, USA

17:06 - 17:18
Influenza virus infection induces high levels of CD12 expression on effector CD8 T cells in the infected lung [AOXI0268]
So Young Chang, University of Melbourne, Australia

Analysis for specificity of SARS-CoV-2 viral titer testing in Ph2a and Ph2b part of ensitrelvir clinical study [AOXI0362]
Keiko Baba, Shionogi & Co., Ltd, Japan

Enhancing Influenza Surveillance through Cloud Computing Platforms [AOXI0084]
Peter Daly, Centers for Disease Control and Prevention, USA

17:18 - 17:30
Efficacy of therapeutic monoclonal antibodies and antiviral drugs against SARS-CoV-2 variants [AOXI0418]
Emi Takashita, National Institute of Infectious Diseases, Japan

Development of an RNA strand-specific hybridization assay to differentiate replicating versus non-replicating influenza A virus [AOXI0252]
Patrick Yang, Centers for Disease Control and Prevention, USA

17:30 - 19:00

Refreshments + Poster Session 3 + sponsored symposium | Hall 1